Cargando…
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
SIMPLE SUMMARY: The tumor mutational burden (TMB) can be defined as the number of somatic mutations per megabase of the sequenced genome. It correlates with tumor neoantigen burden, T cell infiltration, and response to immune checkpoint inhibitors in many solid tumor types. In addition, TMB has been...
Autores principales: | Barroso-Sousa, Romualdo, Pacífico, Jana Priscila, Sammons, Sarah, Tolaney, Sara M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417019/ https://www.ncbi.nlm.nih.gov/pubmed/37568813 http://dx.doi.org/10.3390/cancers15153997 |
Ejemplares similares
-
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
por: Sammons, Sarah, et al.
Publicado: (2023) -
Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019) -
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021) -
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
por: Weis, Luiza N., et al.
Publicado: (2021) -
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
por: O’Meara, Tess A., et al.
Publicado: (2021)